Lin Reviews Long-Term Results from CARTITUDE-1

Yi Lin MD, PhD, a hematologist/oncologist, consultant, Division of Hematology, Department of Internal Medicine, enterprise leader, Cancer Regenerative Medicine, Biotherapeutics, and Biomanufacturing, Mayo Clinic Comprehensive Cancer Center, associate medical director, Center for Regenerative Biotherapeutics, and consultant, Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, discusses the CARTITUDE-1 study (NCT03548207), which investigated ciltacabtagene autoleucel (cilta-cel; Carvykti) for the treatment of relapsed or refractory multiple myeloma.

Transcript:

0:07 | At ASCO this year, I shared the final analysis of the registration trial CARTITUDE-1 study, for which patients with relapsed/refractory multiple myeloma received a single dose of cilta-cel and then were monitored. So, we already know from the primary analysis which has been published, that the response rate is very high for these patients. Ninety-eight percent of patients had some response and close to 83% of these patients had deep responses or a stringent complete response. So, up until this year, we have not seen that median progression-free survival. We looked at 1 year we looked at 2 years, and we looked at close to 2 and a half years. The PFS rate remains quite high, and there was no median PFS. So, now this year was close to 33 months of follow up close to 3 years of follow up.

1:11 | Naturally, we now see that the survival follow up is mature enough. And the median PFS for patients under study was close to 3 years or 35 months. So that is very, very impressive for any therapy in multiple myeloma, particularly in the late-line setting, because all the other treatment we have are continuous treatment until the patient's progress. And this is a one-time dose of CAR T and then patients are just monitored. So, to be treatment free for close to 3 years on average, is very, very impressive.

1:51 | What we're also seeing is because we do know there are patients who had that deep response, including for some patients who were what we call MRD negative, so even deeper, minimal residual disease checks for those patients, the PFS or even longer.